Loading...
Please wait, while we are loading the content...
Similar Documents
Are BET Inhibitors yet Promising Latency-Reversing Agents for HIV-1 Reactivation in AIDS Therapy?
| Content Provider | MDPI |
|---|---|
| Author | Salahong, Thanarat Schwartz, Christian Sungthong, Rungroch |
| Copyright Year | 2021 |
| Description | AIDS first emerged decades ago; however, its cure, i.e., eliminating all virus sources, is still unachievable. A critical burden of AIDS therapy is the evasive nature of HIV-1 in face of host immune responses, the so-called “latency.” Recently, a promising approach, the “Shock and Kill” strategy, was proposed to eliminate latently HIV-1-infected cell reservoirs. The “Shock and Kill” concept involves two crucial steps: HIV-1 reactivation from its latency stage using a latency-reversing agent (LRA) followed by host immune responses to destroy HIV-1-infected cells in combination with reinforced antiretroviral therapy to kill the progeny virus. Hence, a key challenge is to search for optimal LRAs. Looking at epigenetics of HIV-1 infection, researchers proved that some bromodomains and extra-terminal motif protein inhibitors (BETis) are able to reactivate HIV-1 from latency. However, to date, only a few BETis have shown HIV-1-reactivating functions, and none of them have yet been approved for clinical trial. In this review, we aim to demonstrate the epigenetic roles of BETis in HIV-1 infection and HIV-1-related immune responses. Possible future applications of BETis and their HIV-1-reactivating properties are summarized and discussed. |
| Starting Page | 1026 |
| e-ISSN | 19994915 |
| DOI | 10.3390/v13061026 |
| Journal | Viruses |
| Issue Number | 6 |
| Volume Number | 13 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-05-29 |
| Access Restriction | Open |
| Subject Keyword | Viruses Virology Hiv-1 Latently Hiv-1-infected Cell Latency-reversing Agent Bet Protein Brd2 Brd4 Lra Beti Epigenetics Immune Response |
| Content Type | Text |
| Resource Type | Article |
